WallStreetZenWallStreetZen

NASDAQ: ITCI
Intra Cellular Therapies Inc Stock

Overview
ForecastEarningsDividendOwnership
$60.20+0.03 (+0.05%)
Updated May 26, 2023
ITCI Price
$60.20
Fair Value Price
$61.78
Market Cap
$5.77B
52 Week Low
$42.01
52 Week High
$66.56
P/E
-24.98x
P/B
9.2x
P/S
16.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$310.62M
Earnings
-$228.19M
Gross Margin
92.3%
Operating Margin
-73.46%
Profit Margin
-73.5%
Debt to Equity
0.15
Operating Cash Flow
-$247M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ITCI Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Zen Score

–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITCI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ITCI ($60.20) is undervalued by 2.56% relative to our estimate of its Fair Value price of $61.78 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ITCI ($60.20) is not significantly undervalued (2.56%) relative to our estimate of its Fair Value price of $61.78 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ITCI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ITCI due diligence checks available for Premium users.

Be the first to know about important ITCI news, forecast changes, insider trades & much more!

ITCI News

Valuation

ITCI fair value

Fair Value of ITCI stock based on Discounted Cash Flow (DCF)
Price
$60.20
Fair Value
$61.78
Undervalued by
2.56%
ITCI ($60.20) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ITCI ($60.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ITCI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ITCI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-24.98x
Industry
11.86x
Market
54.23x

ITCI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
9.2x
Industry
5.18x
ITCI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ITCI's financial health

Profit margin

Revenue
$95.3M
Net Income
-$44.1M
Profit Margin
-46.2%
ITCI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ITCI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$722.2M
Liabilities
$94.5M
Debt to equity
0.15
ITCI's short-term assets ($706.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITCI's short-term assets ($706.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITCI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ITCI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$60.1M
Investing
-$16.5M
Financing
$3.6M
ITCI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ITCI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ITCI$5.77B+0.05%-24.98x9.20x
IONS$5.83B+4.01%-17.64x11.98x
EXEL$6.23B+0.53%39.85x2.44x
CERE$5.24B+2.55%-13.20x12.13x
MDGL$5.21B+1.17%-15.74x34.70x
View Top Biotech Stocks

Intra Cellular Therapies Stock FAQ

What is Intra Cellular Therapies's quote symbol?

(NASDAQ: ITCI) Intra Cellular Therapies trades on the NASDAQ under the ticker symbol ITCI. Intra Cellular Therapies stock quotes can also be displayed as NASDAQ: ITCI.

If you're new to stock investing, here's how to buy Intra Cellular Therapies stock.

What is the 52 week high and low for Intra Cellular Therapies (NASDAQ: ITCI)?

(NASDAQ: ITCI) Intra Cellular Therapies's 52-week high was $66.56, and its 52-week low was $42.01. It is currently -9.56% from its 52-week high and 43.3% from its 52-week low.

How much is Intra Cellular Therapies stock worth today?

(NASDAQ: ITCI) Intra Cellular Therapies currently has 95,925,601 outstanding shares. With Intra Cellular Therapies stock trading at $60.20 per share, the total value of Intra Cellular Therapies stock (market capitalization) is $5.77B.

Intra Cellular Therapies stock was originally listed at a price of $15.00 in Jan 7, 2014. If you had invested in Intra Cellular Therapies stock at $15.00, your return over the last 9 years would have been 301.33%, for an annualized return of 16.7% (not including any dividends or dividend reinvestments).

How much is Intra Cellular Therapies's stock price per share?

(NASDAQ: ITCI) Intra Cellular Therapies stock price per share is $60.20 today (as of May 26, 2023).

What is Intra Cellular Therapies's Market Cap?

(NASDAQ: ITCI) Intra Cellular Therapies's market cap is $5.77B, as of May 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Intra Cellular Therapies's market cap is calculated by multiplying ITCI's current stock price of $60.20 by ITCI's total outstanding shares of 95,925,601.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.